Expert Opinion on Investigational Drugs
Latest Publications

TOTAL DOCUMENTS

4085

(FIVE YEARS 357)

H-INDEX

90

(FIVE YEARS 10)

Published By Informa Uk (Taylor & Francis)

1744-7658, 1354-3784

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Telacebec: an investigational antibiotic for the treatment of tuberculosis (TB)

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2022.2030309 ◽

2022 ◽

Author(s):

Bei Shi Lee ◽

Kevin Pethe

Download Full-text

Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2022.2030311 ◽

2022 ◽

Author(s):

Hazel Lote ◽

Ian Chau

Keyword(s):

Gastric Cancer ◽

Clinical Trials ◽

Early Phase ◽

Therapeutic Agents ◽

Early Phase Clinical Trials

Download Full-text

The treatment of advanced melanoma: A review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2022.2027366 ◽

2022 ◽

Author(s):

Danielle K. DePalo ◽

Ahmad Tarhini ◽

Jonathan S. Zager

Keyword(s):

Clinical Trials ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Phase 1 ◽

Advanced Melanoma

Download Full-text

New treatment approaches for Alzheimer’s disease: Preclinical studies and clinical trials centered on antidiabetic drugs

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2022.2022122 ◽

2021 ◽

Author(s):

Andreas P. Katsenos ◽

Athena S. Davri ◽

Yannis V. Simos ◽

Ilias P. Nikas ◽

Chryssa Bekiari ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Clinical Trials ◽

Antidiabetic Drugs ◽

Preclinical Studies ◽

Treatment Approaches ◽

Download Full-text

Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2022.2020248 ◽

2021 ◽

Author(s):

Harrison C. Bergeron ◽

Ralph A. Tripp

Keyword(s):

Respiratory Syncytial Virus ◽

Respiratory Tract ◽

Lower Respiratory Tract ◽

Virus Infections ◽

Respiratory Syncytial Virus Infections ◽

Respiratory Tract Illness ◽

Syncytial Virus

Download Full-text

Camrelizumab: an investigational agent for hepatocellular carcinoma

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2022.2022121 ◽

2021 ◽

Author(s):

Bin Xu ◽

Hui-Chuan Sun

Keyword(s):

Hepatocellular Carcinoma ◽

Investigational Agent

Download Full-text

Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2022.2022119 ◽

2021 ◽

Author(s):

Carmen Mignogna ◽

Ernesto Maddaloni ◽

Luca D’Onofrio ◽

Raffaella Buzzetti

Keyword(s):

Type 1 Diabetes ◽

Prevention And Treatment ◽

Investigational Therapies

Download Full-text

Plexiform neurofibroma: shedding light on the investigational agents in clinical trials

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2022.2022120 ◽

2021 ◽

Author(s):

Simge Acar ◽

Amy E. Armstrong ◽

Angela C. Hirbe

Keyword(s):

Clinical Trials ◽

Plexiform Neurofibroma ◽

Investigational Agents

Download Full-text

HPV-induced cancers: preclinical therapeutic advancements

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2021.2010703 ◽

2021 ◽

Author(s):

Lorenzo Messa ◽

Arianna Loregian

Download Full-text

FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2022.2017879 ◽

2021 ◽

Author(s):

Hao Xie ◽

Diego M Alem Glison ◽

Richard D. Kim

Keyword(s):

Hepatocellular Carcinoma ◽

Therapeutic Potential

Download Full-text